Skip to content
Research/Sexual Health/Vibegron

Vibegron

Vibegron is a selective beta-3 adrenergic receptor agonist used primarily for the treatment of overactive bladder (OAB). It works by relaxing the detrusor muscle in the bladder, thereby reducing urinary urgency and frequency. While its direct impact on longevity is limited, managing OAB can significantly improve quality of life and reduce stress-related health issues.

Intelligence Profile

Clinical Applications

Vibegron is primarily used for the management of overactive bladder (OAB), a condition characterized by urinary urgency, frequency, and, often, urge incontinence. Clinical evidence supports its efficacy and safety in treating this condition in various populations, including older adults and specific male and female subgroups.

Overactive Bladder (OAB) Management

  • A systematic review and network meta-analysis compared the safety and efficacy of vibegron with mirabegron and tolterodine, commonly used treatments for OAB. The review found vibegron to be an effective option with a favorable safety profile (European Journal of Obstetrics, Gynecology, and Reproductive Biology, 2026).
  • A multicenter cohort study assessed the real-world persistence of vibegron in patients aged 80 and over with OAB, showing good adherence and effectiveness in long-term use (World Journal of Urology, 2026).

Benign Prostatic Hyperplasia (BPH) in Men

  • Vibegron has been evaluated in managing persistent storage symptoms and OAB in men with benign prostatic hyperplasia (BPH). The narrative review highlighted its potential benefits in alleviating urinary symptoms in this demographic (Advances in Therapy, 2026).

Pediatric Neurogenic Lower Urinary Tract Dysfunction

  • A case report illustrated the use of vibegron in a pediatric patient with anticholinergic-resistant neurogenic lower urinary tract dysfunction following spinal cord amputation. This highlights its potential application in complex pediatric cases, though more research is needed (IJU Case Reports, 2026).
  • An ongoing clinical trial investigates the long-term safety and efficacy of vibegron in pediatric subjects aged 2 to under 18 with neurogenic detrusor overactivity (NDO) (Clinical Trial NCT05491525).

Urgency Urinary Incontinence

  • Vibegron is being compared with onabotulinumtoxinA in an ongoing study to determine its effectiveness for urgency urinary incontinence, suggesting its broader application in related urinary conditions (Clinical Trial NCT05806164).

Overall, vibegron shows promise as an effective treatment for OAB and related conditions, with emerging evidence supporting its use in diverse age groups and complex cases. However, further studies are necessary to fully clarify its role in pediatric and other specialized populations.

Disclaimer: This information is intended for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a healthcare provider with any questions you may have regarding a medical condition.

Free account required

Clinical data requires a free AXIFI account to access clinical data, safety profiles, and research papers.